背景簡(jiǎn)介：

C4d是抗體觸發(fā)補(bǔ)體通過(guò)經(jīng)典途徑活化后C4的裂解產(chǎn)物，能穩(wěn)定地結(jié)合在發(fā)生排斥的移植物內(nèi)皮的表面。檢測(cè)C4d作為機(jī)體針對(duì)同種異體移植物抗體檢測(cè)的一個(gè)間接信號(hào)，大量研究表明：C4d是腎移植免疫中的重要標(biāo)記物，同時(shí)也是心臟、肝及其他器官移植免疫檢測(cè)的重要標(biāo)記物。

產(chǎn)品優(yōu)勢(shì)：

1. 用于檢測(cè)人C4d補(bǔ)體。
2. 該抗體可用于發(fā)光法或用One Lambda 公司的LABScreen® Single Antigen beads流式檢測(cè)細(xì)胞內(nèi)或固相結(jié)合的C4或C4d片段。

產(chǎn)品特點(diǎn)：

1. 檢測(cè)樣本：血清
2. 來(lái)源：兔多克隆抗體
3. 形式：50ul,PE 標(biāo)記純化的IgG片段。
4. 應(yīng)用：Luminex®-檢測(cè)、流式檢測(cè)石蠟及冰凍切片C4d補(bǔ)體。

參考文獻(xiàn)：
1. C4d deposition is associated with inferior kidney allograft outcome independ.of cellular rejection. Regele H. et al., Nephrol Dial Transplant. 2001, 16(10): 2058-2066.
2. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. Böhmig GA et al., J Am Soc Nephrol. 2002, 13(4): 1091-1099.
3. [C4d]FlowPRA screening—a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Wahrmann M et al., Hum Immunol, 2005, 66(5): 526-534
4. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Wahrmann M et al., Am J Transplant, 2006, 6: 1033-1041.
5. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Bartel G et al., Am J Transplant, 2008, 8(1): 41-49
6. Antibodies, isotypes and complement in allograft rejection. Böhmig GA et al., Curr Opin Organ Transplant, 2008, 13(4): 411-418
7. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Bartel G et al., Transpl Int. 2013; 26(2): 121-130.